Open-Label Extension and Safety Study of Talazoparib

NCT02921919

Last updated date
Study Location
Emory University Hospital Midtown
Atlanta, Georgia, 30308, United States
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Cancer
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.

- Female patients of childbearing potential must have a negative pregnancy test before the first dose of talazoparib and must agree to use a highly effective birth control method from the time of the first dose of talazoparib through 45 days after the last dose.

- Male patients must use a condom when having sex with a pregnant woman or with a woman of childbearing potential from the time of the first dose of talazoparib through 105 days after the last dose. Contraception should be considered for a nonpregnant female partner of childbearing potential.

- Female patients may not be breastfeeding at the first dose of talazoparib and must not breastfeed during study participation through 45 days after the last dose of talazoparib.

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Permanently discontinued from any Medivation sponsored study with talazoparib alone or
in combination with another agent.


- Received an antineoplastic therapy or investigational agent after treatment with
talazoparib in the originating protocol.


- Has a clinically significant cardiovascular, dermatologic, endocrine,
gastrointestinal, hematologic, infectious, metabolic, neurologic, psychologic, or
pulmonary disorder or any other condition, including excessive alcohol or drug abuse,
or secondary malignancy, that may interfere with study participation in the opinion of
the investigator.


- Diagnosis of myelodysplastic syndrome (MDS).

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

CancerA Trial To Assess Safety And Tolerability Of PF-04691502 In Cancer Patients NCT00927823
  1. Los Angeles, California
  2. Los Angeles, California
  3. Los Angeles, California
  4. Santa Monica, California
  5. Detroit, Michigan
  6. Amherst, New York
  7. Buffalo, New York
ALL GENDERS
18 Years+
years
MULTIPLE SITES
CancerEvaluation of Dalteparin for Long-term (One Year) Treatment of Blood Clots in Subjects With Cancer NCT00942968
  1. Tuscon, Arizona
  2. Pleasant Hill, California
  3. Torrance, California
  4. Farmington, Connecticut
  5. Norwich, Connecticut
  6. Washington, District of Columbia
  7. Daytona Beach, Florida
  8. Decatur, Georgia
  9. Skokie, Illinois
  10. Louisville, Kentucky
  11. Boston, Massachusetts
  12. Detroit, Michigan
  13. Rochester, New York
  14. Stony Brook, New York
  15. Durham, North Carolina
  16. Bismarck, North Dakota
  17. Philadelphia, Pennsylvania
  18. Houston, Texas
  19. Salt Lake City, Utah
  20. Burlington, Vermont
  21. Charlottesville, Virginia
  22. Graz,
  23. Innsbruck,
  24. Linz,
  25. Linz,
  26. St. Poelten,
  27. Vienna,
  28. Edmonton, Alberta
  29. Vancouver, British Columbia
  30. Halifax, Nova Scotia
  31. London, Ontario
  32. Ottawa, Ontario
  33. Toronto, Ontario
  34. Montreal, Quebec
  35. Montreal, Quebec
  36. Apeldoorn,
  37. Sittard-Geleen,
  38. Barcelona,
  39. Caragena (Murcia),
  40. El Palmar (Murcia),
  41. Girona,
  42. Pamplona,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
CancerOpen-Label Extension and Safety Study of Talazoparib NCT02921919
  1. Atlanta, Georgia
  2. Atlanta, Georgia
  3. Atlanta, Georgia
  4. Atlanta, Georgia
  5. Alhambra, California
  6. Bakersfield, California
  7. Burbank, California
  8. Fullerton, California
  9. Los Angeles, California
  10. Los Angeles, California
  11. Los Angeles, California
  12. Los Angeles, California
  13. Los Angeles, California
  14. Los Angeles, California
  15. Los Angeles, California
  16. Pasadena, California
  17. Porter Ranch, California
  18. Santa Monica, California
  19. Torrance, California
  20. Valencia, California
  21. Orlando, Florida
  22. Pembroke Pines, Florida
  23. Bloomington, Indiana
  24. Fort Wayne, Indiana
  25. Fort Wayne, Indiana
  26. Indianapolis, Indiana
  27. Indianapolis, Indiana
  28. Indianapolis, Indiana
  29. Boston, Massachusetts
  30. Boston, Massachusetts
  31. Ann Arbor, Michigan
  32. Detroit, Michigan
  33. New Brunswick, New Jersey
  34. Houston, Texas
  35. Edmonton, Alberta
  36. Hamilton, Ontario
  37. Montreal, Quebec
  38. Marseille cedex 09,
  39. Erlangen,
  40. Budapest,
  41. Budapest,
  42. Chisinau,
  43. Warszawa,
  44. Moscow,
  45. Saint-Petersburg,
  46. Sutton, Surrey
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Open-Label Extension and Safety Study of Talazoparib
Official Title  ICMJE A SINGLE-ARM, OPEN-LABEL, MULTICENTER, EXTENDED TREATMENT, SAFETY STUDY IN PATIENTS TREATED WITH TALAZOPARIB
Brief Summary This is a single-arm, open-label, extended treatment, safety study in patients treated with talazoparib in qualifying studies.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Cancer
Intervention  ICMJE Drug: Talazoparib
Maximum starting dose: 1mg/day or last tolerated dose in the originating protocol
Other Name: MDV3800
Study Arms  ICMJE Experimental: Talazoparib
Intervention: Drug: Talazoparib
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Enrolling by invitation
Estimated Enrollment  ICMJE
 (submitted: September 29, 2016)
150
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE September 30, 2020
Estimated Primary Completion Date September 30, 2020   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Eastern Cooperative Oncology Group (ECOG) performance status ? 2.
  • Female patients of childbearing potential must have a negative pregnancy test before the first dose of talazoparib and must agree to use a highly effective birth control method from the time of the first dose of talazoparib through 45 days after the last dose.
  • Male patients must use a condom when having sex with a pregnant woman or with a woman of childbearing potential from the time of the first dose of talazoparib through 105 days after the last dose. Contraception should be considered for a nonpregnant female partner of childbearing potential.
  • Female patients may not be breastfeeding at the first dose of talazoparib and must not breastfeed during study participation through 45 days after the last dose of talazoparib.

Exclusion Criteria:

  • Permanently discontinued from any Medivation sponsored study with talazoparib alone or in combination with another agent.
  • Received an antineoplastic therapy or investigational agent after treatment with talazoparib in the originating protocol.
  • Has a clinically significant cardiovascular, dermatologic, endocrine, gastrointestinal, hematologic, infectious, metabolic, neurologic, psychologic, or pulmonary disorder or any other condition, including excessive alcohol or drug abuse, or secondary malignancy, that may interfere with study participation in the opinion of the investigator.
  • Diagnosis of myelodysplastic syndrome (MDS).
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Canada,   France,   Germany,   Hungary,   Moldova, Republic of,   Poland,   Russian Federation,   United Kingdom,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT02921919
Other Study ID Numbers  ICMJE MDV3800-13
C3441010 ( Other Identifier: Alias Study Number )
2016-001972-31 ( EudraCT Number )
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE
Plan to Share IPD:Yes
Plan Description:Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/d….
URL:https://www.pfizer.com/science/clinical_trials/trial_data_and_results/d…
Responsible Party Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Medivation, Inc.
Investigators  ICMJE
Study Director:Pfizer Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date March 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP